Read an important notice regarding the data security incident McKesson reported on August 28, 2026. Read more.
USOR 25230 - Ph3 trial of BNT324 versus docetaxel in metastatic castration-resistant prostate cancer
A Phase III, randomized, open-label trial of BNT324 versus docetaxel with prednisone/prednisolone in metastatic castration-resistant prostate cancer
Disease Types: Prostate
Available at: Arlington Heights, Chicago, Niles